Paul F. Truex is Director at Anthera Pharmaceuticals Inc (ANTH). They have made 6 open-market trades across 3 companies since 2010, most recently 2022-05-31.
CIK 0001120362
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $74K since 2010, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MIST | BUY | 2022-05-31 | 2022-06-01 | $5.60 | $28K | -4.9% | +3.2% | +49.8% |
| ANTH | BUY | 2017-09-07 | 2017-09-07 | $1.34 | $7K | N/A | N/A | N/A |
| ANTH | BUY | 2012-06-29 | 2012-07-02 | $0.76 | $15K | N/A | N/A | N/A |
| ANTH | SELL · 10b5-1 | 2012-02-15 | 2012-02-17 | $7.84 | $118K | N/A | N/A | N/A |
| ANTH | SELL · 10b5-1 | 2012-01-17 | 2012-01-19 | $6.75 | $101K | N/A | N/A | N/A |
| ANTH | SELL · 10b5-1 | 2011-12-15 | 2011-12-16 | $6.34 | $95K | N/A | N/A | N/A |
| ANTH | SELL · 10b5-1 | 2011-11-15 | 2011-11-17 | $6.96 | $104K | N/A | N/A | N/A |
| ANTH | SELL · 10b5-1 | 2011-10-21 | 2011-10-25 | $6.25 | $145K | N/A | N/A | N/A |
| ANTH | SELL · 10b5-1 | 2011-10-18 | 2011-10-20 | $6.25 | $42K | N/A | N/A | N/A |
| TSRX | BUY | 2011-08-29 | 2011-08-31 | $6.80 | $14K | N/A | N/A | N/A |
| ANTH | SELL · 10b5-1 | 2011-07-15 | 2011-07-18 | $7.95 | $119K | N/A | N/A | N/A |
| ANTH | SELL · 10b5-1 | 2011-06-15 | 2011-06-17 | $8.30 | $125K | N/A | N/A | N/A |
| ANTH | SELL · 10b5-1 | 2011-05-16 | 2011-05-18 | $7.16 | $107K | N/A | N/A | N/A |
| TSRX | BUY | 2010-11-23 | 2010-11-24 | $3.50 | $4K | N/A | N/A | N/A |
| ANTH | BUY | 2010-03-01 | 2010-03-02 | $7.12 | $7K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.